Omeros Corporation (OMER) : During the past 4 weeks, traders have been relatively bearish on Omeros Corporation (OMER), hence the stock is down -2.46% when compared to the S&P 500 during the same period. However, in the past 1 week, the selling of the stock is down by -7.97% relative to the S&P 500. The 4-week change in the price of the stock is -1.46% and the stock has fallen -7.92% in the past 1 week.
The stock has recorded a 20-day Moving Average of 1.73% and the 50-Day Moving Average is 1.67%. Omeros Corporation (NASDAQ:OMER): stock turned positive on Friday. Though the stock opened at $11.36, the bulls momentum made the stock top out at $11.6298 level for the day. The stock recorded a low of $11.36 and closed the trading day at $11.51, in the green by 1.23%. The total traded volume for the day was 567,100. The stock had closed at $11.37 in the previous days trading.
The company Insiders own 13.6% of Omeros Corporation shares according to the proxy statements. Institutional Investors own 55.53% of Omeros Corporation shares. During last six month period, the net percent change held by insiders has seen a change of -3.92%. Also, Cantor Fitzgerald initiates coverage on Omeros Corporation (NASDAQ:OMER). Cantor Fitzgerald has a Buy rating on the shares. As per the latest report, the brokerage house announces the price target to $21 per share. The rating by the firm was issued on June 2, 2016.
Omeros Corporation is a biopharmaceutical company. The Company is engaged in discovering, developing and commercializing small-molecule and protein therapeutics for large-market as well as orphan indications targeting inflammation, coagulopathies and disorders of the central nervous system. Its marketed drug product Omidria is approved in the United States for use during cataract surgery or intraocular lens (IOL), which is replacement surgery, to maintain pupil size by preventing intraoperative miosis (pupil constriction) and to reduce postoperative ocular pain. Omidria is derived from its PharmacoSurgery platform, which is for patients undergoing ophthalmological, arthroscopic, urological and other surgical procedures. It also has six clinical-stage development programs in its pipeline, which includes a group of preclinical programs as well as two additional platforms: one capable of unlocking new G protein-coupled receptor, drug targets and the other used to generate antibodies.